Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

NCT00415636 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: IC83/LY2603618
DRUG: IC83/LY2603618
DRUG: IC83/LY2603618
DRUG: IC83/LY2603618
DRUG: IC83/LY2603618
DRUG: pemetrexed
DRUG: pemetrexed

Sponsor

Eli Lilly and Company